. 2014 Aug 21;78(3):477–487. doi: 10.1111/bcp.12355

Table 2.

Mean (± SD) denosumab PK parameters after multiple dose subcutaneous administration of 30, 120, and 180 mg Q4W

		Dose 1		Dose 3			Dose 5			Dose 6
Dose (mg)		C_{1 week} (ng ml⁻¹)	AUC(0,τ) (ng ml⁻¹ day)	C_{2 weeks} (ng ml⁻¹)	AUC(0,τ) (ng ml⁻¹day)	AR₁	C_{2 weeks} (ng ml⁻¹)	AUC(0,τ) (ng ml⁻¹ day)	AR₂	C_{2 weeks} (ng ml⁻¹)	t_1/2,z (day)
30	n	33	33	39	39	–	39	39	–	34	19
	Mean	3190	67900	7300	152000	2.24	7830	168000	2.47	6090	26.1
	SD	1390	28600	3940	81300	2.84	4320	80100	2.80	3360	10.1
	%CV^*	43.4	42.1	54.0	53.4	1.27	55.2	47.8	1.14	55.1	38.8
120	n	34	34	36	36	–	35	35	–	35	29
	Mean	13500	287000	22800	539000	1.88	27100	723000	2.52	20500	28.8
	SD	6140	130000	9440	215000	1.66	14500	684000	5.26	13500	9.5
	%CV^*	45.5	45.3	41.4	40.0	0.883	54.7	94.5	2.09	65.8	32.9
180	n	36	36	39	39	–	38	38	–	33	28
	Mean	22000	478000	46300	1030000	2.15	45300	1090000	2.27	38200	34.8
	SD	7300	154000	20300	381000	2.48	15300	356000	2.31	13000	12.4
	%CV^*	33.2	32.1	43.9	37.1	1.16	33.8	32.7	1.02	34.0	35.6

Percent coefficient of variation = (SD/Mean) × 100. SD, standard deviation; PK, pharmacokinetics; C_{1 week}, serum concentration 1 week post-dose; C_{2 weeks}, serum concentration 2 weeks post-dose; AUC(0,τ), area under the concentration–time curve from time zero to day 84; t_1/2,z, terminal phase half-life; accumulation ratio (AR₁) = (AUC(0,τ), dose 3)/(AUC(0,τ), dose 1); accumulation ratio (AR₂) = (AUC(0,τ), dose 5)/(AUC(0,τ), dose 1).